STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Clinical trials for STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immune-boosting drug shows promise in ovarian cancer fight
Disease control OngoingThis early-phase study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced ovarian, fallopian tube, or primary peritoneal cancer. About 18 people with stage III or IV cancer will receive the combination. The main goal is to me…
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Heated chemo during surgery may fight ovarian cancer return
Disease control OngoingThis early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Ovarian cancer drug trial aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …
Matched conditions: STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC